Skip to main navigation Skip to search Skip to main content

EuroGuiderm guideline on lichen sclerosus-Treatment of lichen sclerosus

  • G. Kirtschig*
  • , M. Kinberger
  • , A. Kreuter
  • , R. Simpson
  • , A. Guenthert
  • , C. van Hees
  • , K. Becker
  • , M. J. Ramakers
  • , M. Corazza
  • , S. Mueller
  • , S. von Seitzberg
  • , M. J. Boffa
  • , R. Stein
  • , G. Barbagli
  • , C. C. Chi
  • , J. N. Dauendorffer
  • , B. Fischer
  • , M. Gaskins
  • , E. Hiltunen-Back
  • , A. Hoefinger
  • N. H. Koellmann, H. Kuehn, H. K. Larsen, M. Lazzeri, W. Mendling, A. F. Nikkels, M. Promm, K. K. Rall, S. Regauer, M. Sardy, N. Sepp, T. Thune, A. Tsiogka, S. Vassileva, L. Voswinkel, L. Woelber, R. N. Werner
*Corresponding author for this work
  • Free University of Berlin
  • Humboldt University of Berlin
  • Dept Dermatol Venereol & Allergol
  • University of Nottingham
  • University of Ferrara
  • University of Basel
  • Department of Dermatology
  • Ruprecht Karl University of Heidelberg
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • Assistance publique – Hôpitaux de Paris
  • Switzerland Verein Lichen Sclerosus eV
  • University of Helsinki
  • University of Copenhagen
  • Department Urology
  • Witten/Herdecke University
  • University of Liege
  • University of Regensburg
  • Eberhard Karls University of Tübingen
  • Medical University of Graz
  • Semmelweis University
  • Ordensklinikum Elisabethinen Linz
  • University of Bergen
  • National and Kapodistrian University of Athens
  • Medical University Sofia
  • University of Hamburg

Research output: Contribution to journal › Article › Academic

56 Citations (Scopus)
939 Downloads (Pure)

Abstract

Introduction: Lichen sclerosus (LS) is an inflammatory skin disease affecting all ages. LS typically involves the anogenital site where it causes itching and soreness; it may lead to sexual and urinary dysfunction in females and males; however, it may be asymptomatic. First signs of LS are usually a whitening of the genital skin, sometimes preceded by redness and oedema; fissuring, scarring, shrinkage and fusion of structures may follow in its course. LS is associated with an increased risk of genital cancer. LS has a huge impact on the quality of life of affected patients, and it is important to raise more awareness of this not uncommon disease in order to diagnose and treat it early. Objectives: The guideline intends to provide guidance on the diagnostic of LS (part 1), highlight important aspects in the care of LS patients, generate recommendations and treatment algorithms (part 2) on topical, interventional and surgical therapy, based on the latest evidence, provide guidance in the management of LS patients during pregnancy, provide guidance for the follow-up of patients with LS and inform about new developments and potential research aspects. Materials and Methods: The guideline was developed in accordance with the EuroGuiDerm Methods Manual v1.3 https://www.edf.one/de/home/Guidelines/EDF-EuroGuiDerm.html. The wording of the recommendations was standardized (as suggested by the GRADE Working Group). The guideline development group is comprised of 34 experts from 16 countries, including 5 patient representatives. Results: Ultrapotent or potent topical corticosteroids in females and males, adults and children remain gold standard of care for genital LS; co-treatment with emollients is recommended. If standard treatment fails in males, a surgical intervention is recommended, complete circumcision may cure LS in males. UV light treatment is recommended for extragenital LS; however, there is limited scientific evidence. Topical calcineurin inhibitors are second line treatment. Laser treatment, using various wave lengths, is under investigation, and it can currently not be recommended for the treatment of LS. Treatment with biologics is only reported in single cases. Conclusions: LS has to be diagnosed and treated as early as possible in order to minimize sequelae like scarring and cancer development. Topical potent and ultrapotent corticosteroids are the gold standard of care; genital LS is often a lifelong disease and needs to be treated long-term.
Original languageEnglish
Pages (from-to)1874-1909
Number of pages36
JournalJournal of the European Academy of Dermatology and Venereology
Volume38
Issue number10
Early online dateJun 2024
DOIs
Publication statusPublished - Oct 2024

Bibliographical note

Publisher Copyright:
© 2024 European Academy of Dermatology and Venereology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'EuroGuiderm guideline on lichen sclerosus-Treatment of lichen sclerosus'. Together they form a unique fingerprint.

Cite this